Status:

COMPLETED

Basal Tumours in Bladder Cancer, Response to chemoTherapy

Lead Sponsor:

University Hospital, Rouen

Collaborating Sponsors:

Institut Curie

APHP

Conditions:

Bladder Cancer

Chemotherapy Effect

Eligibility:

All Genders

18-80 years

Brief Summary

Determine the sensitivity/resistance to chemotherapy of the various subgroups of muscle-invasive bladder cancers, including the basal subgroup (about 25% of these tumours) according to 4 different cla...

Eligibility Criteria

Inclusion

  • Inclusion Criteria of Patients enrolled in VESPER study:
  • Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine included in VESPER cohort and :
  • having signed an informed consent form for the participation to the collection or
  • dead/lost to follow-up without prior opposition expressed against research program,
  • genetic analysis will only be carried out for patients who have signed the genetic consent form.
  • Inclusion Criteria of Patients from St Louis cohort not enrolled in VESPER study:
  • Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine included in Saint-Louis cohort and :
  • having received an informed form for the participation to the collection and not having expressed opposition against research program within 1 month or
  • dead/lost to follow-up without prior opposition expressed against research program,
  • Exclusion Criteria:
  • Patients enrolled in VESPER study:Tumors from patient having withdrawn his/her informed consent form for the participation to the collection and/or VESPER project.
  • OR
  • Patients from St Louis not enrolled in VESPER study:Tumors from patient having expressed opposition against research program after 1 month for the participation to the collection.

Exclusion

    Key Trial Info

    Start Date :

    February 27 2019

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    April 29 2019

    Estimated Enrollment :

    293 Patients enrolled

    Trial Details

    Trial ID

    NCT04089748

    Start Date

    February 27 2019

    End Date

    April 29 2019

    Last Update

    June 6 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    DRCI

    Rouen, France, 76000

    Basal Tumours in Bladder Cancer, Response to chemoTherapy | DecenTrialz